Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PREPRINT WATCH

The CD58–CD2 axis in cancer immune evasion

Nature Reviews Immunology volume 22, page 409 (2022)Cite this article

Subjects

Cancer immune evasion following treatment is a major issue for immunotherapies such as immune checkpoint blockade (ICB), whereby adaptive resistance to treatment can occur following an initial response, leading to poor prognosis.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

Original article

Related article

Download references

Author information

Authors and Affiliations

  1. Preprint Club, University of Oxford, Oxford, UK

    Max Quastel & Michael Dustin

Authors
  1. Max Quastel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Dustin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Max Quastel or Michael Dustin.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Quastel, M., Dustin, M. The CD58–CD2 axis in cancer immune evasion. Nat Rev Immunol 22, 409 (2022). https://doi.org/10.1038/s41577-022-00738-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-022-00738-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing